Strides Pharma Science Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/yt1jnnsup3r36b5kev93u4b3.pdf

Key Takeaways


US & Regulated Markets Performance


OneSource: The CDMO Growth Engine

Arun Kumar: "you should strongly believe that all engines are on fire and yes this is a good space to be. And I think we are all very excited about every small bit of our business in OneSource."

The Biosecurity Act Opportunity


Softgel CDMO: A New Vertical


Financial Health & Capital Allocation

Arun Kumar: "We would have brought down debt in the last 3 years from a high of INR3,000 crores to INR1,500 crores just through internal operations – I mean, operational efficiencies, which is also a testament to our teamwork here, our great focus on efficiencies and compliance."

Guidance & Commitments

CommitmentSpecificsTimeline
Overall EBITDA guidanceINR 950 crores to INR 1,000 crores, including OneSource; trending toward higher endFY '25
Retained business EBITDAINR 750 crores to INR 800 crores; business will continue to grow from that sizeFY '25
OneSource EBITDA$59 million to $60 million, trending toward higher end; exit quarter EBITDA of $20 millionFY '25
OneSource exit quarter EBITDA run rateVery close to 40%As early as FY '25
Net debt-to-EBITDATracking ahead of guidance of less than 2xFY '25
Effective tax rateRemain in 17% to 20% rangeFY '25
NCLT process outcomePositive news expected; stock listing within 60 days of outcomeBefore end of calendar year 2024
Teriparatide European launchAll approvals in placeQ4 FY '25
Liraglutide commercializationStarting from Q4Q4 FY '25
GLP capacity sell-out4 crore units sold out, 6 to 8 months ahead of scheduleAhead of original schedule
Semaglutide commercializationPossible in some countries aligned with patent expiryJanuary to March '26
Net cash targetCompany expects to be net cashBy FY '27
$400 million revenue strategyReaffirmedFY '27-'28
OneSource revenue target$350 million to $400 millionOver next 3 to 4 years

Key Metrics

MetricQ2 FY25
Revenue (US)$75 million for the year
H1 revenue growth17%
EBITDA₹236 cr, highest ever reported
H1 EBITDA₹452 cr, 45–47% of guided range
Reported PAT₹93 cr
Adjusted PAT (ex-OneSource depreciation and interest)₹100 cr, highest ever reported
Gross margin59–60% target range; 75 bps sequential decline due to elevated access market business and lower European sales
EBITDA guidance (FY25, including OneSource)₹950 cr to ₹1,000 cr
Retained business EBITDA guidance (FY25)₹750 cr to ₹800 cr
US commercialized products71, up from new approvals and dormant product launches
US revenue milestone (FY27–28)$400 million strategy reaffirmed
Other regulated markets growth3–4% short of target growth rate
OneSource revenue guidance (FY25)$160 million to $180 million with 34% EBITDA margin
OneSource EBITDA guidance (FY25)$59 million to $60 million, exit quarter EBITDA of $20 million
OneSource annualized exit run rate$80 million
OneSource revenue target (3–4 years)$350 million to $400 million
OneSource exit quarter EBITDA margin~40%
CDMO win ratio~40%
Softgel capacity expansionAdditional 100 crore units planned for next year; current additional capacity fully sold out
Cash-to-cash cycle126 days
Cash flow from operations (H1)₹418 cr on H1 EBITDA of ₹453 cr
Capex spend (H1)₹92 cr
Net debt₹1,902 cr, reduction of ₹133 cr in H1
Net Debt-to-EBITDA2.1x, tracking ahead of <2x guidance for FY25
ROCE17.2%, improved from 12.8% in FY24
Net interest costs (quarter)₹54 cr, aided by interest income on tax refunds
Effective tax rate17%, expected to remain in 17–20% range for FY25
GLP commercial supply agreements expected in FY265 to 7 unique customers
Contracted GLPs7 out of 8 commercially
Revenue growth guidance (FY25)15%, trending at 17% toward higher end